Commonwealth Equity Services LLC increased its stake in shares of Tilray Inc (NASDAQ:TLRY) by 9.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,148 shares of the company’s stock after acquiring an additional 2,549 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Tilray were worth $721,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds also recently bought and sold shares of TLRY. ETF Managers Group LLC bought a new position in Tilray during the 2nd quarter worth approximately $92,004,000. Think Investments LP purchased a new stake in Tilray in the 2nd quarter worth approximately $7,031,000. Morgan Stanley lifted its holdings in Tilray by 44.2% in the 2nd quarter. Morgan Stanley now owns 330,527 shares of the company’s stock worth $15,390,000 after buying an additional 101,375 shares during the period. Vanguard Group Inc. purchased a new stake in Tilray in the 2nd quarter worth approximately $3,484,000. Finally, Stelac Advisory Services LLC purchased a new stake in Tilray in the 2nd quarter worth approximately $3,000,000. Institutional investors and hedge funds own 7.76% of the company’s stock.
Several research firms have weighed in on TLRY. Jefferies Financial Group set a $25.00 price objective on Tilray and gave the stock a “hold” rating in a report on Friday, October 25th. Benchmark reiterated a “buy” rating and issued a $40.00 price objective (down previously from $80.00) on shares of Tilray in a report on Wednesday, November 13th. Piper Jaffray Companies dropped their price objective on Tilray from $72.00 to $31.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. MKM Partners dropped their price objective on Tilray from $34.00 to $26.00 and set a “neutral” rating for the company in a report on Thursday. Finally, Zacks Investment Research upgraded Tilray from a “sell” rating to a “hold” rating in a report on Friday, October 25th. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have given a buy rating to the stock. Tilray currently has a consensus rating of “Hold” and an average target price of $43.13.
Tilray (NASDAQ:TLRY) last released its earnings results on Tuesday, November 12th. The company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.05). The firm had revenue of $51.10 million during the quarter, compared to analysts’ expectations of $49.57 million. Tilray had a negative net margin of 97.39% and a negative return on equity of 43.60%. The company’s revenue for the quarter was up 411.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.08) EPS. Equities analysts anticipate that Tilray Inc will post -1.27 EPS for the current year.
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Featured Article: Most Active Stocks: Dollar Volume vs Share Volume
Want to see what other hedge funds are holding TLRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tilray Inc (NASDAQ:TLRY).
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.